# Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

> **NCT04639843** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Adult T-cell Leukemia/Lymphoma
- Extranodal NK-/T-cell Lymphoma, Nasal Type
- Enteropathy-Associated T-Cell Lymphoma
- Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma

## Interventions

- **DRUG:** CC-486 (5-azacitidine)
- **DRUG:** Duvelisib
- **DRUG:** Romidepsin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT04639843
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-03
- **Primary completion:** 2022-11-03
- **Final completion:** 2022-11-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Safety issues with PI3 kinase inhibitors
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639843, "Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04639843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*